Literature DB >> 21532611

Moving forward toward a cure for Parkinson's: neuropathology of the nigrostriatal pathway determines the location of growth factor delivery.

Terence R Flotte1, Robert M Frederickson, Pedro R Lowenstein, Christian Mueller.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21532611      PMCID： PMC3098651          DOI： 10.1038/mt.2011.76

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  9 in total

1.  Clinical protocol. Administration of a replication-deficient adeno-associated virus gene transfer vector expressing the human CLN2 cDNA to the brain of children with late infantile neuronal ceroid lipofuscinosis.

Authors:  Ronald G Crystal; Dolan Sondhi; Neil R Hackett; Stephen M Kaminsky; Stefan Worgall; Philip Stieg; Mark Souweidane; Syed Hosain; Linda Heier; Douglas Ballon; Miles Dinner; Krystyna Wisniewski; Michael Kaplitt; Bruce M Greenwald; Joy D Howell; Kristin Strybing; Jonathan Dyke; Henning Voss
Journal:  Hum Gene Ther       Date:  2004-11       Impact factor: 5.695

2.  Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics.

Authors:  Artur V Cideciyan; Tomas S Aleman; Sanford L Boye; Sharon B Schwartz; Shalesh Kaushal; Alejandro J Roman; Ji-Jing Pang; Alexander Sumaroka; Elizabeth A M Windsor; James M Wilson; Terence R Flotte; Gerald A Fishman; Elise Heon; Edwin M Stone; Barry J Byrne; Samuel G Jacobson; William W Hauswirth
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-22       Impact factor: 11.205

3.  Recombinant adeno-associated virus vector: use for transgene expression and anterograde tract tracing in the CNS.

Authors:  N L Chamberlin; B Du; S de Lacalle; C B Saper
Journal:  Brain Res       Date:  1998-05-18       Impact factor: 3.252

4.  Aspartoacylase gene transfer to the mammalian central nervous system with therapeutic implications for Canavan disease.

Authors:  P Leone; C G Janson; L Bilaniuk; Z Wang; F Sorgi; L Huang; R Matalon; R Kaul; Z Zeng; A Freese; S W McPhee; E Mee; M J During; L Bilianuk
Journal:  Ann Neurol       Date:  2000-07       Impact factor: 10.422

5.  Anterograde axonal transport of AAV2-GDNF in rat basal ganglia.

Authors:  Agnieszka Ciesielska; Gabriele Mittermeyer; Piotr Hadaczek; Adrian P Kells; John Forsayeth; Krystof S Bankiewicz
Journal:  Mol Ther       Date:  2010-11-23       Impact factor: 11.454

6.  Effect of gene therapy on visual function in Leber's congenital amaurosis.

Authors:  James W B Bainbridge; Alexander J Smith; Susie S Barker; Scott Robbie; Robert Henderson; Kamaljit Balaggan; Ananth Viswanathan; Graham E Holder; Andrew Stockman; Nick Tyler; Simon Petersen-Jones; Shomi S Bhattacharya; Adrian J Thrasher; Fred W Fitzke; Barrie J Carter; Gary S Rubin; Anthony T Moore; Robin R Ali
Journal:  N Engl J Med       Date:  2008-04-27       Impact factor: 91.245

7.  Safety and efficacy of gene transfer for Leber's congenital amaurosis.

Authors:  Albert M Maguire; Francesca Simonelli; Eric A Pierce; Edward N Pugh; Federico Mingozzi; Jeannette Bennicelli; Sandro Banfi; Kathleen A Marshall; Francesco Testa; Enrico M Surace; Settimio Rossi; Arkady Lyubarsky; Valder R Arruda; Barbara Konkle; Edwin Stone; Junwei Sun; Jonathan Jacobs; Lou Dell'Osso; Richard Hertle; Jian-xing Ma; T Michael Redmond; Xiaosong Zhu; Bernd Hauck; Olga Zelenaia; Kenneth S Shindler; Maureen G Maguire; J Fraser Wright; Nicholas J Volpe; Jennifer Wellman McDonnell; Alberto Auricchio; Katherine A High; Jean Bennett
Journal:  N Engl J Med       Date:  2008-04-27       Impact factor: 91.245

8.  Results from a phase I safety trial of hAADC gene therapy for Parkinson disease.

Authors:  J L Eberling; W J Jagust; C W Christine; P Starr; P Larson; K S Bankiewicz; M J Aminoff
Journal:  Neurology       Date:  2008-04-09       Impact factor: 9.910

9.  Efficient retrograde neuronal transduction utilizing self-complementary AAV1.

Authors:  Edmund R Hollis; Ken Kadoya; Matthew Hirsch; Richard J Samulski; Mark H Tuszynski
Journal:  Mol Ther       Date:  2007-11-27       Impact factor: 11.454
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.